As of Mar 27
| +6.02 / +6.50%|
The 9 analysts offering 12-month price forecasts for Synageva BioPharma Corp have a median target of 113.00, with a high estimate of 125.00 and a low estimate of 88.00. The median estimate represents a +14.50% increase from the last price of 98.69.
The current consensus among 10 polled investment analysts is to Buy stock in Synageva BioPharma Corp. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.